Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Dra. Natalia Prego; España, 1 Dr. Fernando Ania; España, 1 Dr. Angel R. Valdepeñas; España, 1
Dra. Beatriz, Rauber; Argentina, 2 Dra. Tatiana Campos; Costa Rica, 3 Dr. Wilfredo Stocks; Guatemala,4
Dr. Víctor Andrade; Perú, 5 Dr. Atilio Farina; Paraguay, 6 Dr. Juan U. Arrúa; Paraguay, Brazil, 6, 7
Dr. Dan Macias; Chile, 8 Dra. Margarita Oliveira; Portugal, 9 Dra. Stefania Pallini; Italia, 10
Dra. Sally Priester; Puerto Rico, Estados Unidos de América 11
Los MÉDICOS POR LA VERDAD DEL MUNDO, es una Coalición de Médicos y Científicos
Protegiendo la Libertad y la Defensa de la Salud de los Pacientes de todo el Mundo. Todos con la
sólida experiencia en Medicina, Salud Pública y Publicaciones Científicas. Médicos con más de
veinte años tratando pacientes con vocación exitosa en la medicina, defienden el Juramento
Hipocrático, respetando la vida desde la concepción hasta la muerte natural con el compromiso
de no hacer daño. Médicos y Científicos con derecho a la objeción de conciencia como personas.
Apoyamos el derecho al consentimiento informado de los tratamientos disponibles, apoyando
que las personas tenga el derecho de elegir el tratamiento o rechazar cualquier protocolo de salud.
Las Constituciones de nuestras Naciones, con la diversidad de lenguajes, todas sostenemos como
evidentes estas verdades: que todos los hombres son creados iguales; que son dotados, por su
CREADOR de Derechos inalienables, que entre estos están la Vida, la Libertad y la búsqueda de
la felicidad; que para garantizar estos derechos, se instituyen entre los hombres los gobiernos,
que derivan sus poderes legítimos del consentimiento de los gobernados; que cuando quiera que
una forma de gobierno se haga destructora de estos principios, el pueblo tiene el derecho a
reformarla o abolirla e instituir un nuevo gobierno que se funde en dichos principios, y a
organizar sus poderes en la forma que a su juicio ofrecerá las mayores probabilidades de
alcanzar su seguridad y felicidad.
Las naciones de todo el mundo tienen el panorama de la democracia con la conclusión de
mantener la libertad y elegir y ejercer soberanamente los derechos soberanos inalienables
representados como el poder supremo de los pueblos vivos que buscan alcanzar la verdad y la
plenitud de la felicidad. De lo contrario, esa nación estaría bajo tiranía.
Dado que es deber de todas las naciones reconocer la providencia de Dios Todopoderoso,
obedecer Su voluntad, estará agradecida por Sus beneficios y humildemente implorará Su
protección y favor. 12
Alden Bradford (ed.). Speeches of the Governors of Massachusetts, from 1765 to 1775, and the
answer of the House of Representatives to the Same; With their Resolutions and Addresses for
that period (Boston, 1818). microfiche. 50. LAC 15249
Las limitaciones a los derechos humanos en una crisis sanitaria no deben ser excesivas y son
inaceptables. Una emergencia no cambia la Constitución de las Naciones y una Emergencia no
puede ser perenne. El principio de proporcionalidad tiene el mismo fin en todas partes: moderar
el poder de los poderes públicos para garantizar los derechos y la autonomía de las personas y
evitar la vulneración de sus derechos inalienables, con la preservación de nuestros derechos
esenciales. Toda persona tiene derecho a la vida, a la libertad y a la seguridad de su persona la
promoción del respeto universal y la observancia de los derechos humanos y las libertades
fundamentales. 13
https://www.un.org/sites/un2.un.org/files/udhr.pdf
Las especificaciones médicas analíticas y estudios científicos de esta última emergencia de datos
de incidencia y mortalidad con diferentes grados de confianza son fundamental para el control
de cualquier enfermedad y enfermedad de emergencia. Esto también indica diferencias con
protocolos particulares. La exposición para ver pacientes en un tiempo resulta caracterizada por
los datos que se han generado a través de la colaboración internacional de médicos y científicos
anónimos de todo el mundo.
En la historia, la Medicina es un campo que requiere datos e inteligencia. Por eso es importante
comunicar, debatir y cooperar, donde se requiere confianza basada en la ética y la competencia
frente al despotismo universal y la privación de la autonomía defendida de las personas, la
política y las economías.
Desde el 2020, la Libertad de Ciencia que viene establecida en el Art. 27 de la Declaración
Universal de los Derechos humanos se ha convertido en una violación normal mundial,
igualmente una violación a la libertad de tratamiento y método a usar con el paciente, estos
especialmente protegidas por los Códigos de Deontología Médica en todo el mundo.
Estas políticas locales, estatales, y en muchas naciones que han adoptado la política global
de la ONU (OMS) a los que no se alinien a estos nuevos mecanismos que no son compatible con
la Ciencia, con la medicina de décadas, persigen las Libertades de médicos, científicos, pacientes,
tratamiento y método impidiendo de esta forma el verdadero avance y progreso de la ciencia. En
la historia ningun caso ha pertenecido jamás a las instituciones oficiales. Sino a investigadores y
científicos individuales, a menudo a lo largo de la historia jamás vinculados a corporaciones
oficiales.
En los últimos dos años hemos tenido una expansión global de vigilancia que puede demostrar
su multiplicación de equipos de Red Telefónica y despliegue de redes 5G.
(Lo que no condujo a una Consulta al Pueblo).
Los Pueblos de las Naciones no han sido consultados a través de sus gobiernos, asamblea y
secretarios y/o ministros de salud a través de las Constituciones, que son la base para que
acordemos que nos gobiernan o no.
Tenemos muy claro que falta la Consulta al Pueblo y No rotundo de nuestro Consentimiento a
las Naciones Unidas.
Confiamos en que nuestra Constitución será respetada para seguir viviendo plenamente nuestros
derechos Inalienables Soberanos, Civiles y Constitucionales para preservar nuestra Libertad,
Libertad de Expresión, Libertad de Movimiento, Asociación y Felicidad.
Todo lo fundado en Dios confiamos.
Dado que la OMS no es una agencia policial de vigilancia que pueda imponer fácilmente
sanciones a los Estados Parte por el incumplimiento de las obligaciones legales, tampoco puede
disponer para mejorar el cumplimiento de las Naciones.
Serán las naciones las que decidan, a través de la agencia de confianza local adecuada, si
participarán en cualquier ensayo de vacuna con las DECISIONES DEL PACIENTE SERÁN
REVISADAS CON LOS ESTÁNDARES MÁS ALTOS DE PRINCIPIOS ÉTICOS,
INVESTIGACIÓN BASADA EN REGISTROS Y UN CONSENTIMIENTO INFORMADO
ADECUADO.
OMS pretende enmendar 13 artículos del IHR: 5, 6, 9, 10, 11, 12, 13, 15, 18, 48, 49, 53, 59. 17
https://apps.who.int/gb/ebwha/pdf_files /WHA75/A75_18-es.pdf
Porque la OMS es inmune a “toda forma de proceso legal” bajo un documento acordado por
los Estados Unidos a través de las Naciones Unidas llamado Convención sobre los Privilegios
e Inmunidades de las Agencias Especializadas.
Debido a que los CDC dicen que deben detener y examinar a las personas que sospechan que
pueden tener una enfermedad, deben tener un desencadenante legal, y ese desencadenante es su
definición. Su definición les permite eludir el sistema legal de los Estados Unidos. El término
“emergencia de salud pública” nunca se definió en la ley.
En 2017, el CDC actualizó sus regulaciones con respecto a la cuarentena y el aislamiento. Los
cambios se finalizaron en el registro público el último día de la presidencia de Barack Obama, el
19 de enero de 2017. Parte de esos cambios incluyeron alinear la definición de emergencia de
salud pública de EE. UU. con la de la OMS.
“HHS/CDC considera esencial definir una emergencia de salud pública porque la existencia de
tal emergencia es un requisito previo necesario para la aprehensión y el examen de personas en
la etapa pre transmisible de una enfermedad transmisible en cuarentena.” 18
https://www.federalregister.gov/documents/2017/01/19/2017-00615/control-de-
enfermedades-transmisibles
Respetuosamente,
No estamos aceptando la intención de la OMS de los 13 artículos del IHR. Todas las voces
cuentan, sin dejar atrás a nadie ni a ninguna nación. “Todas las Naciones que aman a Dios,
aman a sus Naciones y la Libertad no pueden estar actuando en contra de los Fundamentos de
nuestra Constitución”. 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 ,43 , 4, 45, 46, 47, 48, 49,
50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87,
88, 89, 90, 91, 92, 9, 94, 95, 96, 97, 98, 99. 100-166
Referencias
1. THE CONSTITUTION OF ESPAÑOLA, Dr. Natalia Prego, Dr. Fernando Ania, Dr. Angel R.
Valdepeñas
2. THE CONSTITUTION OF ARGENTINA, Dr. Beatriz, Rauber
3. THE CONSTITUTION OF COSTA RICA, Dr. Tatiana Campos
4. THE CONSTITUTION OF THE REPUBLIC OF GUATEMALA y PACTO DE LA
DECLARACIÓN DE SAN JOSÉ EN COSTA RICA, Dr. Wilfredo Stocks
5. THE CONSTITUTION OF PERU, Dr. Victor Andrade
6. THE CONSTITUTION OF PARAGUAY, Dr. Atilio Farina; Paraguay, Dr. Juan U. Arrua
7. THE CONSTITUTION OF BRAZIL Dr. Juan U. Arrua
8. THE CONSTITUTION OF CHILE, Dr. Dan Macias
9. THE CONSTITUTION OF PORTUGAL, Dr. Margarita Oliveira; Portugal
10. THE CONSTITUTION OF ITALY, Dr. Stefania Pallini, Italy
11. THE CONSTITUTION OF THE UNITED STATES OF AMERICA, PR., Dr. Sally Priester
12. Alden Bradford (ed.). Speeches of the Governors of Massachusetts, from 1765 to 1775, and the
answer of the House of Representatives to the Same; With their Resolutions and Addresses for that
period (Boston, 1818). microfiche. 50. LAC 15249 https://commonlaw.earth/the-nuremberg-
principles/
13. https://www.un.org/sites/un2.un.org/files/udhr.pdf
14. https://commonlaw.earth/the-nuremberg-principles/
15. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-
medical-research-involving-human-subjects/
16. www.fda.gov/Biologics License Application (BLA) BioNTech/COVID19-COMINARTY/FINAL
REPORT 2027.
17. https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_18-en.pdf
18. https://www.federalregister.gov/documents/2017/01/19/2017-00615/control-of-
communicable-diseases
19. https://www.ecfr.gov/current/title-42/chapter-I/subchapter-F/part-70
20. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute
Coronary Syndrome as measured by PULS cardiac testing: a
caution: https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
21. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal
hemoglobinuria: https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-
vaccines-induce-severe-hemolysis-in
22. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-
19 (AZD1222) vaccine: a multicenter observational cohort
study: https://pubmed.ncbi.nlm.nih.gov/34313952/
23. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34510014/.
24. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine
treatment – A report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/34510694/
25. Neuromyelitis Optica in a healthy woman after vaccination against severe acute respiratory
syndrome coronavirus 2 mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34660149/
26. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in
persons aged 75 years or older: https://pubmed.ncbi.nlm.nih.gov/34807248/
27. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute
pulmonary embolism complications and follow-up: https://pubmed.ncbi.nlm.nih.gov/34804412/
28. Beware of neuromyelitis Optica spectrum disorder after vaccination with inactivated virus for
COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/
29. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2
30. vaccination: https://pubmed.ncbi.nlm.nih.gov/33932458/
31. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-
2: https://pubmed.ncbi.nlm.nih.gov/34250318/.
32. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/
33. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature
review: https://pubmed.ncbi.nlm.nih.gov/34342187/
34. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34000278/
35. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/34352309/
36. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19
vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34242687/.
37. Myocarditis and other cardiovascular complications of mRNA-based COVID-19
vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
38. Be alert to the risk of adverse cardiovascular events after COVID-19
vaccination: https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033
39. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19
vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-
complications-of-the-mrna-based-covid-19-vaccines
40. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis
after COVID-19 mRNA vaccination: a case series: https://jcmr-
online.biomedcentral.com/articles/10.1186/s12968-021-00795-4
41. COVID-19 vaccine-associated acute cerebral venous thrombosis and pulmonary artery embolism
https://pubmed.ncbi.nlm.nih.gov/34247246/
42. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19
vaccine: https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce
nts_Receiving.95800.aspx
43. A look at the role of postmortem immunohistochemistry in understanding the inflammatory
pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative
review: https://pubmed.ncbi.nlm.nih.gov/34769454/
44. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2
vaccination: https://pubmed.ncbi.nlm.nih.gov/34846583/
45. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with
adenovirus and after COVID-
19: https://www.sciencedirect.com/science/article/pii/S0735109721051949
46. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after
immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with
conventional heparin-warfarin based
anticoagulation: https://www.sciencedirect.com/science/article/pii/S1871402121002046
47. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2
vaccine: https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098
48. Cerebral venous sinus thrombosis after vaccination: the United Kingdom
experience: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext
49. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with
Ad26.COV2.S (against covid-19), March 2 to April 21,
2020: https://pubmed.ncbi.nlm.nih.gov/33929487/
50. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in
subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society
for the Study of Hemostasis and Thrombosis (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
51. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after
vaccination with COVID-19; a systematic
review: https://www.sciencedirect.com/science/article/pii/S0022510X21003014
52. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus
thrombosis after vaccination with
Ad26.COV2.S: https://www.sciencedirect.com/science/article/pii/S0196064421003425
53. A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-
19 vaccination: https://www.sciencedirect.com/science/article/pii/S0735675721005714
54. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two
cases in the United
Kingdom: https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X
55. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the
management of cerebral venous thrombosis related to COVID-19
vaccination: https://www.sciencedirect.com/science/article/pii/S0213485321000839
56. COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data
from VigiBase: https://pubmed.ncbi.nlm.nih.gov/33863748/
57. Cerebral venous thrombosis associated with the covid-19 vaccine in
Germany: https://onlinelibrary.wiley.com/doi/10.1002/ana.26172
58. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-
CoV-2: a black swan event: https://pubmed.ncbi.nlm.nih.gov/34133027/
59. The importance of recognizing cerebral venous thrombosis following anti-COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/34001390/
60. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after
immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with
conventional heparin-warfarin-based
anticoagulation:. https://www.sciencedirect.com/science/article/pii/S1871402121002046.
61. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after
covid-19 vaccination; a systematic review: https://pubmed.ncbi.nlm.nih.gov/34365148/.
62. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally
associated with administration of COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33917902/
63. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
64. Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-
19: a missed opportunity for a rapid return on
experience: https://pubmed.ncbi.nlm.nih.gov/34033927/
65. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune
thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/33914590/
66. Venous sinus thrombosis after vaccination with ChAdOx1 nCov-
19: https://pubmed.ncbi.nlm.nih.gov/34420802/
67. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases
reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
68. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with
Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort
study: https://pubmed.ncbi.nlm.nih.gov/33952445/
69. Cerebral venous thrombosis associated with COVID-19 vaccine in
Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/
70. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of
vaccine-induced immune-mediated thrombotic
thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34341358/
71. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/33845870/.
72. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination:
are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
73. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after
immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with
conventional heparin-warfarin-based anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
74. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA
vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/
75. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA
vaccine: https://pubmed.ncbi.nlm.nih.gov/33687691/
76. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous
thrombosis with high mortality rate: a case series: https://pubmed.ncbi.nlm.nih.gov/34393988/.
77. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia
(VITT) and cerebral sinus venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/.
78. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19
vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
79. Cerebral venous thrombosis following COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/34045111/.
80. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral
venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
81. Cerebral venous thrombosis associated with COVID-19 vaccine in
Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/.
82. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological
management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
83. Cerebral venous thrombosis and thrombocytopenia after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/33878469/.
84. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two
cases in the United Kingdom: https://pubmed.ncbi.nlm.nih.gov/33857630/.
85. Cerebral venous thrombosis induced by SARS-CoV-2
vaccine: https://pubmed.ncbi.nlm.nih.gov/34090750/.
86. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic
thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34333995/
87. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2
vaccine: https://pubmed.ncbi.nlm.nih.gov/34111775/.
88. Cerebral venous thrombosis after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/34045111/
89. Lethal cerebral venous sinus thrombosis after COVID-19
vaccination: https://pubmed.ncbi.nlm.nih.gov/33983464/
90. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with
adenovirus and after COVID-19: https://pubmed.ncbi.nlm.nih.gov/34116145/
91. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by
intravascular administration of the vaccine: https://pubmed.ncbi.nlm.nih.gov/34286453/.
92. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination:
are these reports merely coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
93. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain
MRI: https://pubmed.ncbi.nlm.nih.gov/34244448/
94. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus
thrombosis after vaccination with Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34226070/
95. Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-
19: https://pubmed.ncbi.nlm.nih.gov/33845870/.
96. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA
vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/.
97. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral
venous sinus thrombosis (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
98. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases
reported to the European Medicines Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
99. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca
vaccination: https://pubmed.ncbi.nlm.nih.gov/34274191/
100. WHO. International Health Regulations (2005). 2nd edition. Geneva, Switzerland: World Health
Organization; 2008. http://whqlibdoc.who.int/publications/2008/9789241580410_ eng.pdf.
Accessed June 29, 2015.
101. WHO. Report of the Ebola Interim Assessment Panel. July 2015.
http://who.int/csr/resources/publications/ebola/report- by-panel.pdf. Accessed July 30, 2015.
102. WHO. 2014 Ebola virus disease outbreak and follow-up to the Special Session of the Executive
Board on Ebola. May 23, 2015.
http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_ACONF5- en.pdf. Accessed June 29,
2015.
103. Moon S, Sridhar D, Pate MA, et al. Will Ebola change the game? Ten essential reforms before the
next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to
Ebola. Lancet. 2015;386(10009):2204-2221.
104. Moon S, Sridhar D, Pate MA, et al. Will Ebola change the game? Ten essential reforms before the
next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to
Ebola. Lancet. 2015;386(10009):2204-2221.
105. Commission on a Global Health Risk Framework for the Future. The Neglected Dimension of Global
Security: A Framework to Counter Infectious Disease Crises. Washington, DC: National Academy of
Medicine; 2016. www.nam.edu/GHRF. Accessed January 30, 2016.
106. UN Secretary-General. Press release: Secretary-General appoints high-level panel on global
response to health crises. April 2015. http://www.un.org/press/en/2015/sga1558.doc.htm.
Accessed De- cember 10, 2015.
107. White House. Global Health Security Agenda: toward a world safe and secure from infectious
disease threats. 2014. http://www. globalhealth.gov/global-health-topics/global-health-
security/ GHS%20Agenda.pdf. Accessed February 25, 2016.
108. White House. Fact sheet: the U.S. commitment to the Global Health Security Agenda. November
16, 2015. https://www. whitehouse.gov/the-press-office/2015/11/16/fact-sheet-us-
commitment-global-health-security-agenda. Accessed December 4, 2015.
109. G7. G7 Leaders’ Declaration. June 8, 2015. http://www. interaction.org/document/2015-g7-
leaders-declaration. Accessed June 30, 2015.
110. Howard-Jones N. The scientific background of the Inter- national Sanitary Conferences, 1851–
1938. Geneva, Switzer- land: WHO; 1975. http://whqlibdoc.who.int/publications/
1975/14549_eng.pdf. Accessed June 30, 2015.
111. Gostin LO. Global Health Law. Cambridge, MA, and London, UK: Harvard University Press; 2014.
112. WHO. WHO Constitution. 1946. http://whqlibdoc.who.int/
hist/official_records/constitution.pdf. Accessed June 30, 2015.
113. WHA. Revision and updating of the International Health Regu- lations. WHA48.7. 1995.
114. WHA. Global health security: epidemic alert and response. WHA54.14 2001.
115. WHA. Global public health response to natural occurrence, acci- dental release or deliberate use
of biological and chemical agents or radionuclear material that affect health. WHA55.16. 2002.
Heymann DL. The international response to the outbreak of SARS in 2003. Phil Trans R Soc Lond
B. 2004;359(1447):1127- 1129. http://rstb.royalsocietypublishing.org/content/royptb/359/
1447/1127.full.pdf. Accessed June 30, 2015.
116. Fleck F. How SARS changed the world in less than six months. Bull World Health Organ.
2003;81(8):625-626. http://www. who.int/bulletin/volumes/81/8/News0803.pdf?ua=1.
Accessed June 30, 2015.
117. Heymann DL, Mackenzie JS, Peiris M. SARS legacy: outbreak reporting is expected and
respected. Lancet. 2013;381(9869):779- 781.
118. WHO. States Parties to the International Health Regulations
119. (2005). http://www.who.int/ihr/legal_issues/states_parties/en/. Accessed June 30, 2015.
120. WHO. IHR Core Capacity Monitoring Framework: Checklist and Indi- cators for Monitoring Progress in
the Development of IHR Core Capacities in States Parties. Geneva, Switzerland: WHO; 2013.
http://www. who.int/ihr/checklist/en/. Accessed April 2014.
121. Katz R. Use of revised International Health Regulations dur- ing influenza A (H1N1) epidemic,
2009. Emerg Infect Dis. 2009;15(8):1165-1170.
122. McNeil DG Jr. W.H.O. estimate of swine flu deaths in 2009 rises sharply. New York Times.
November 27, 2013. http:// www.nytimes.com/2013/11/27/health/who-revises-estimate-of-
swine-flu-deaths.html. Accessed June 30, 2015.
123. WHO. Swine influenza: statement by WHO Director-General, Dr Margaret Chan. April 27, 2009.
http://www.who.int/media centre/news/statements/2009/h1n1_20090427/en/. Accessed July
1, 2015.
124. WHO. Implementation of the International Health Regula- tions (2005): responding to public
health emergencies: report by the Director-General. May 15, 2015: para. 10. http://apps.
who.int/gb/ebwha/pdf_files/WHA68/A68_22-en.pdf. Accessed July 1, 2015.
125. WHO. Implementation of the International Health Regula- tions (2005): report of the Review
Committee on the Func- tioning of the International Health Regulations (2005) in Relation to
Pandemic (H1N1) 2009. Doc. A64/10. May 5, 2011.
http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_10- en.pdf. Accessed Aug 3, 2015.
126. WHO. Statement on the 5th IHR Emergency Committee meeting regarding the international
spread of wild poliovirus. May 5, 2015.
http://www.who.int/mediacentre/news/statements/2015/polio- 5th-statement/en/. Accessed
July 1, 2015.
127. Horton R. A plan to protect the world—and save WHO. Lancet. 2015; 386(9989):103.
128. Associated Press. Emails: UN health agency resisted declaring Ebola emergency. New York Times.
March 20, 2015. http://www.nytimes.com/aponline/2015/03/20/world/ap- un-who-bungling-
ebola.html. Accessed June 30, 2015.
129. WHO. Statement on the meeting of the International Health Regulations Emergency Committee
regarding the 2014 Ebola out- break in West Africa. August 8, 2014. http://www.who.int/media
centre/news/statements/2014/ebola-20140808/en/. Accessed Au- gust 3, 2015.
130. WHO. Ebola virus disease outbreak. www.who.int/csr/disease/ ebola/en/. Accessed December
10, 2015.
131. Fauci AS, Morens DM. Zika virus in the Americas: yet another arbovirus threat. N Engl J Med.
Published online January 13, 2016. doi:10.1056/NEJMp1600297.
132. Lucey DR, Gostin LO. The emerging Zika pandemic: enhanc- ing preparedness. JAMA. Published
online January 27, 2016. doi:10.1001/jama.2016.0904.
133. WHO and PAHO. Epidemiological alert: neurological syndrome, congenital malformations, and
Zika virus infection: implica- tions for public health in the Americas. December 1, 2015.
http://www.paho.org/hq/index.php?option=com_content&view=
article&id=11599&Itemid=41691&lang=en. Accessed January 31, 2016.
134. Petersen EE, Staples JE, Meaney-Delman D, et al. Interim guide- lines for pregnant women
during a Zika virus outbreak—United States, 2016. Morb Mortal Wkly Rep. 2016;65(2):30-33.
135. WHO. Director-General summarizes the outcome of the Emergency Committee regarding
clusters of microcephaly and Guillain-Barre ́ syndrome. February 1, 2016. http://www.who.int/
mediacentre/news/statements/2016/emergency-committee-zika- microcephaly/en/. Accessed
February 25, 2016.
136. WHO. Statement on the first meeting of the International Health Regulations (2005) (IHR 2005)
Emergency Committee on Zika virus and observed increase in neurological disorders and
neonatal malformations. February 1, 2016. http://www.who.
int/mediacentre/news/statements/2016/1st-emergency- committee-zika/en/. Accessed
February 25, 2016.
137. Lucey DR. MERS in Korea: why this outbreak can be stopped soon. Center for Strategic and
International Studies. June 7, 2015.
http://csis.org/files/publication/150608_MERS%20in%20Korea
%20Why%20This%20Outbreak%20Can%20Be%20Stopped% 20Soon.pdf. Accessed July 1, 2015.
138. WHO. Emergency Committee—9th meeting summary: briefing notes on MERS-CoV. June 22,
2015. http://www.who.int/ mediacentre/news/mers/briefing-notes/update-22-june-2015/en/.
Accessed July 1, 2015.
139. Gostin LO, Lucey DR. Middle East respiratory syndrome: a global health challenge. JAMA.
Published online June 17, 2015. http://jama.jamanetwork.com/article.aspx?articleID=2338303.
Accessed July 1, 2015.
140. WHO. Statement on the eighth meeting of the IHR Emergency Committee regarding MERS-CoV.
February 5, 2015. http://www. who.int/mediacentre/news/statements/2015/8th-mers-emer-
gency-committee/en/. Accessed July 1, 2015.
141. Gostin LO, Friedman EA. A retrospective and prospective analysis of the West African Ebola
virus disease epidemic: robust national health systems at the foundation and an empowered
WHO at the apex. Lancet. 2015;385:1902-1909.
142. WHO. Implementation of the International Health Regula- tions (2005): report of the Review
Committee on Second Extensions for Establishing National Public Health Capaci- ties and on IHR
Implementation: report by the Director- General. March 27, 2015: para. 17.
http://apps.who.int/gb/ebwha/ pdf_files/WHA68/A68_22Add1-en.pdf. Accessed June 29,
2015.
143. Phu TD, Long VN, Hien NT, et al. Strengthening global health security capacity—Vietnam
demonstration project, 2013. Morb Mortal Wkly Rep. 2014;63(4):77-80.
144. Lescano AG, Salmon-Mulanovich G, Pedroni E, Blazes DL. Outbreak investigation and response
training. Science. 2007; 318(5850):574-575.
145. United Nations Development Group (UNDG)—Western and Central Africa. Socio-Economic
Impact of Ebola Virus Disease in West African Countries. Addis Ababa, Ethiopia: UNDG; 2015.
http://www.africa.undp.org/content/dam/rba/docs/Reports/ebola- west-africa.pdf. Accessed
January 31, 2016.
146. Gostin LO, Friedman EA. Ebola: a crisis in global health leader- ship. Lancet. 2014;384:1323-1325.
147. WHO. Report by the Director-General to the Executive Board at its 138th session. January 25,
2016. EB 138/2.
148. Fidler DP, Gostin LO. The WHO Pandemic Influenza Prepared- ness Framework: a milestone in
global governance for health. JAMA. 2011;306(2):200-201.
149. WHO. Advisory Group on Reform of WHO’s Work in Outbreaks and Emergencies with Health
and Humanitarian Consequences. http://www.who.int/about/who_reform/emergency-
capacities/advisory-group/en/. Accessed December 10, 2015.
150. WHO. Review Committee on the Role of the Interna- tional Health Regulations (2005) in the
Ebola Outbreak and Response. http://www.who.int/ihr/review-committee-2016/en/.
151. WHO. Global Policy Group statement on reforms of WHO work in outbreaks and emergencies.
January 30, 2016. http://www. who.int/dg/speeches/2016/reform-statement/en/. Accessed
Jan- uary 31, 2016.
152. Jha A, Kickbusch I, Taylor P, Abbasi K. Accelerating achievement of the sustainable development
goals: a game changer in global health. BMJ. 2016;352:i409. doi:10.1136/bmj.i409.
153. Boateng L. Perspectives in global health security: effective preven- tion, detection and response to
global pandemics. CRDF Global Sponsored Briefing. Washington, DC. October 2015.
154. The Lancet. Ebola: what lessons for the International Health Reg- ulations? Lancet.
2014;384(9951):1321. http://www.thelancet. com/journals/lancet/article/PIIS0140-
6736(14)61697-4/fulltext. Accessed March 6, 2015.
155. Buse K, Gostin LO, Friedman EA. Pathways towards a framework convention on global health:
political mobilization for the human right to health. In: Freeman M, Hawkes S, Bennett B, eds.
Law and Global Health. Current Legal Issues, vol. 16. London, UK: Oxford University Press; 2014.
156. WHO. Frequently asked questions on IHR Emergency Commit- tee.
http://www.who.int/ihr/procedures/en_ihr_ec_faq.pdf. Ac- cessed July 3, 2015.
157. WHO. Statement on the second meeting of the IHR Emergency Committee concerning MERS-
CoV. July 17, 2013. http:// www.who.int/mediacentre/news/statements/2013/mers_cov_
20130717/en/. Accessed July 3, 2015.
158. WHO. Statement on the meeting of the International Health Regulations Emergency Committee
concerning the international spread of wild poliovirus. May 5, 2014. http://www.who.int/
entity/mediacentre/news/statements/2014/polio-20140505/ en/index.html. Accessed July 3,
2015.
159. WHO. Statement on the ninth meeting of the IHR Emergency Committee regarding MERS-CoV.
June 17, 2015. http://www. who.int/mediacentre/news/statements/2015/ihr-ec-mers/en/. Ac-
cessed July 3, 2015.
160. WHO. Emergency Response Framework. 2013: p. 19. http://
apps.who.int/iris/bitstream/10665/89529/1/9789241504973_ eng.pdf?ua=1. Accessed July 2,
2015.
161. WHO. Current WHO phases of pandemic alert for Pandemic (H1N1) 2009.
http://www.who.int/csr/disease/swineflu/phase/en/. Accessed August 3, 2015.
162. Standley CJ, Sorrell EM, Kornblet S, Vaught A, Fischer JE, Katz R. New framework for global
public health emer- gency reporting and response. Science. 2015;348(6236):762-763.
doi:10.1126/science.aaa5521.
163. FAO, WHO, OIE, WTO. Joint FAO/WHO/OIE/WTO state- ment on influenza A (H1N1) and the
safety of pork. May 2, 2009. http://www.who.int/mediacentre/news/statements/2009/
h1n1_20090502/en/. Accessed July 1, 2015.
164. FAO, WHO, OIE. Joint FAO/WHO/OIE statement on influenza A (H1N1) and the safety of pork.
May 7, 2009. http://www.who. int/mediacentre/news/statements/2009/h1n1_20090430/en/.
Ac- cessed July 5, 2015.
165. WHO. Implementation of the International Health Regula- tions (2005). May 24, 2014. WHA67.13.
http://apps.who.int/ gb/ebwha/pdf_files/WHA67/A67_R13-en.pdf. Accessed Decem- ber 16,
2015.
166. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored
vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination
cluster-randomised trial. Lancet. Published online July 31, 2015.
http://dx.doi.org/10.1016/S0140-6736(15)61117-5.